← Back to Screener
Ardelyx, Inc. (ARDX)
Price$5.56
Value ScoreD
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-12.06%
Price vs S&P 500 (4W)-17.98%
VGM Score54.87
Market Capitalization$1.37B
All Metrics
Book Value / Share (Quarterly)$0.60
P/TBV (Annual)10.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)98.40%
Cash Flow / Share (Quarterly)$-0.15
Price vs S&P 500 (YTD)-12.79%
Gross Margin (TTM)92.51%
Net Profit Margin (TTM)-13.58%
EPS (TTM)$-0.24
10-Day Avg Trading Volume2.98M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)121.91%
EPS (Annual)$-0.26
ROI (Annual)-16.66%
Gross Margin (Annual)90.29%
Net Profit Margin (5Y Avg)-354.96%
Cash / Share (Quarterly)$0.96
Revenue Growth QoQ (YoY)27.47%
ROA (Last FY)-12.28%
Revenue Growth TTM (YoY)18.24%
EBITD / Share (TTM)$-0.14
ROE (5Y Avg)-71.79%
Operating Margin (TTM)-8.75%
Cash Flow / Share (Annual)$-0.18
P/B Ratio9.24x
P/B Ratio (Quarterly)9.88x
Net Income / Employee (Annual)$-126,000
EV / Revenue (TTM)3.61x
Net Interest Coverage (TTM)-2.02x
ROA (TTM)-11.85%
EV / EBITDA (TTM)712.35x
EPS Incl Extra (Annual)$-0.26
Current Ratio (Annual)4.31x
Quick Ratio (Quarterly)2.93x
3-Month Avg Trading Volume3.70M
52-Week Price Return52.75%
Revenue / Employee (TTM)$874,600
Tangible BV / Share (Quarterly)$0.82
P/S Ratio (Annual)3.37x
Asset Turnover (Annual)0.81x
52-Week High$8.40
Operating Margin (5Y Avg)-343.95%
EPS Excl Extra (Annual)$-0.26
CapEx CAGR (5Y)36.06%
Tangible BV CAGR (5Y)-6.73%
26-Week Price Return-4.14%
Quick Ratio (Annual)3.80x
13-Week Price Return-11.32%
Total Debt / Equity (Annual)1.21x
Current Ratio (Quarterly)3.49x
Enterprise Value$1.55B
Revenue / Share Growth (5Y)82.05%
Asset Turnover (TTM)0.87x
Book Value / Share Growth (5Y)-12.70%
Revenue / Employee (Annual)$833,000
Inventory Turnover (Annual)2.03x
Pretax Margin (Annual)-14.89%
Cash / Share (Annual)$1.08
3-Month Return Std Dev47.70%
Gross Margin (5Y Avg)88.61%
Net Income / Employee (TTM)$-118,700
ROE (Last FY)-36.90%
Net Interest Coverage (Annual)-1.69x
EPS Basic Excl Extra (Annual)$-0.26
P/FCF (TTM)66.04x
Receivables Turnover (TTM)6.61x
EV / Free Cash Flow (TTM)976.57x
Total Debt / Equity (Quarterly)1.37x
EPS Incl Extra (TTM)$-0.24
Receivables Turnover (Annual)6.29x
ROI (TTM)-16.36%
P/S Ratio (TTM)3.21x
Pretax Margin (5Y Avg)-354.79%
Revenue / Share (Annual)$1.69
Tangible BV / Share (Annual)$0.50
Forward P/E41.34x
Price vs S&P 500 (52W)28.38%
Year-to-Date Return-4.63%
5-Day Price Return-2.97%
EPS Normalized (Annual)$-0.26
ROA (5Y Avg)-36.87%
Net Profit Margin (Annual)-15.12%
Month-to-Date Return-7.95%
Cash Flow / Share (TTM)$0.01
EBITD / Share (Annual)$-0.16
Operating Margin (Annual)-10.06%
LT Debt / Equity (Annual)1.21x
ROI (5Y Avg)-50.13%
LT Debt / Equity (Quarterly)1.37x
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)5.32x
P/B Ratio (Annual)8.48x
Inventory Turnover (TTM)1.38x
Pretax Margin (TTM)-13.55%
Book Value / Share (Annual)$0.68
Price vs S&P 500 (13W)-19.58%
Beta0.65x
P/FCF (Annual)119.02x
Revenue / Share (TTM)$1.74
ROE (TTM)-38.11%
52-Week Low$3.49
vGradeD
gGradeB
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.15est. -0.15
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.50
4.50
4.50
4.47
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARDXArdelyx, Inc. | D | B | C | $5.56 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Ardelyx Inc is a biopharmaceutical company developing first-in-class medicines for unmet medical needs using a proprietary platform designed to minimize side effects and drug-drug interactions. The company's marketed products include IBSRELA (tenapanor) for irritable bowel syndrome with constipation in adults, and XPHOZAH (tenapanor) for reducing serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to or intolerance of phosphate binders.